Patents by Inventor John R. Sedy

John R. Sedy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulation of ?? T cells
    Patent number: 10759863
    Abstract: The present invention relate to the discovery that BTLA, IL-7 and ROR?t modulate the activity and expression of ??T cells. Specifically, the present invention provides methods of modulating ??T cell homeostasis and function by regulating expression of BTLA. The present invention further provides agents which modulate the activity and expression of BTLA, RORyt and IL-7 and methods for screening of such agents. The present invention also provides methods for treating autoimmune or inflammatory diseases using modulators of BTLA, RORyt and IL-7.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: September 1, 2020
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Carl F. Ware, John R. Sedy
  • MODULATION OF GAMMA DELTA T CELLS
    Publication number: 20160194403
    Abstract: The present invention relate to the discovery that BTLA, IL-7 and ROR?t modulate the activity and expression of ??T cells. Specifically, the present invention provides methods of modulating ??T cell homeostasis and function by regulating expression of BTLA. The present invention further provides agents which modulate the activity and expression of BTLA, RORyt and IL-7 and methods for screening of such agents. The present invention also provides methods for treating autoimmune or inflammatory diseases using modulators of BTLA, RORyt and IL-7.
    Type: Application
    Filed: September 4, 2014
    Publication date: July 7, 2016
    Inventors: Carl F. WARE, John R. SEDY
  • Compositions and methods for modulating lymphocyte activity
    Patent number: 9045562
    Abstract: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: June 2, 2015
    Assignee: Washington University
    Inventors: Kenneth M. Murphy, Theresa L. Murphy, John R. Sedy, Michelle A. Hurchla Pyles, Norihiko Watanabe, Jianfei Yang
  • Compositions and methods for modulating lymphocyte activity
    Patent number: 8546541
    Abstract: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: October 1, 2013
    Assignee: Washington University
    Inventors: Kenneth M. Murphy, Theresa L. Murphy, John R. Sedy, Michelle A. Hurchla Pyles, Norihiko Watanabe, Jianfei Yang
  • COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
    Publication number: 20120322986
    Abstract: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: May 17, 2012
    Publication date: December 20, 2012
    Applicant: THE WASHINGTON UNIVERSITY
    Inventors: Kenneth M. Murphy, Theresa L. Murphy, John R. Sedy, Michelle A. Hurchla Pyles, Norihiko Watanabe, Jianfei Yang
  • COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
    Publication number: 20120207759
    Abstract: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: December 30, 2011
    Publication date: August 16, 2012
    Applicant: THE WASHINGTON UNIVERSITY
    Inventors: Kenneth M. Murphy, Theresa L. Murphy, John R. Sedy, Michelle A. Hurchla Pyles, Norihiko Watanabe, Jianfei Yang
  • COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
    Publication number: 20110230647
    Abstract: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.
    Type: Application
    Filed: December 23, 2010
    Publication date: September 22, 2011
    Applicant: THE WASHINGTON UNIVERSITY
    Inventors: Kenneth M. Murphy, Theresa L. Murphy, John R. Sedy, Michelle A. Hurchla Pyles, Norihiko Watanabe, Jianfei Yang